Be part of the knowledge.™

Breast Cancer and Breast Health

33

LikeLikedUnlike

Episodes 16-30 of 40

Understanding CNS Lesions in HER2+ Metastatic Breast Cancer
MinuteCE®
Understanding CNS Lesions in HER2+ Metastatic Breast Cancer
- Sarah Sammons, MD
  Peer
1.00 program credits
Systemic Management of Brain Metastases in HER2+ BC: Emerging Strategies and Treatment Approaches
MinuteCE®
Systemic Management of Brain Metastases in HER2+ BC: Emerging Strategies and Treatment Approaches
- Carey Anders, MD, FASCO
  Peer
1.00 program credits
Optimizing Treatment Selection for HER2+ Breast Cancer Patients with Brain Metastases
MinuteCE®
Optimizing Treatment Selection for HER2+ Breast Cancer Patients with Brain Metastases
- Carey Anders, MD, FASCO
  Peer
- Sarah Sammons, MD
  Peer
1.00 program credits
Virtual Tumor Board: Maximizing the Potential of Immuno-Oncology in Early TNBC Through Personalized Care
CME/CE
Virtual Tumor Board: Maximizing the Potential of Immuno-Oncology in Early TNBC Through Personalized Care
- Heather McArthur, MD
  Peer
- Margaret Gatti-Mays, MD, MPH
  Peer
0.25 credits
MinuteCE®
Innovations in Oncology Learning Center: From Guidelines to Practice—Breast Cancer
- William J. Gradishar, MD
  Peer
- Erica L. Mayer, MD, MPH
  Peer
- Peter Schmid, FRCP, MD, PhD
  Peer
1.50 credits 10 episodes
Immunotherapy for TNBC in the Perioperative Setting: Clinical Evidence and Considerations
MinuteCE®
Immunotherapy for TNBC in the Perioperative Setting: Clinical Evidence and Considerations
- Peter Schmid, FRCP, MD, PhD
  Peer
1.50 program credits
advertisement
Adjuvant Treatments for HR+/HER2- EBC: The Role of CDK4/6 and PARP Inhibitors
MinuteCE®
Adjuvant Treatments for HR+/HER2- EBC: The Role of CDK4/6 and PARP Inhibitors
- Erica L. Mayer, MD, MPH
  Peer
1.50 program credits
Clinical Implications of Current Guidelines on First-Line Immunotherapy and PARP Inhibitors for TNBC
MinuteCE®
Clinical Implications of Current Guidelines on First-Line Immunotherapy and PARP Inhibitors for TNBC
- Peter Schmid, FRCP, MD, PhD
  Peer
1.50 program credits
The Role of HER2-Directed Therapy for Second-Line Treatment of HER2+ Metastatic Breast Cancer
MinuteCE®
The Role of HER2-Directed Therapy for Second-Line Treatment of HER2+ Metastatic Breast Cancer
- Peter Schmid, FRCP, MD, PhD
  Peer
1.50 program credits
Guideline Recommendations for the Definition and Treatment of HER2-Low Breast Cancer
MinuteCE®
Guideline Recommendations for the Definition and Treatment of HER2-Low Breast Cancer
- Erica L. Mayer, MD, MPH
  Peer
1.50 program credits
Emerging Treatment Approaches for EBC
MinuteCE®
Emerging Treatment Approaches for EBC
- William J. Gradishar, MD
  Peer
1.50 program credits
The Evolving Treatment Landscape for MBC: Emerging Therapies
MinuteCE®
The Evolving Treatment Landscape for MBC: Emerging Therapies
- William J. Gradishar, MD
  Peer
1.50 program credits
advertisement
Expert Viewpoint: Optimizing Breast Cancer Treatment
MinuteCE®
Expert Viewpoint: Optimizing Breast Cancer Treatment
- William J. Gradishar, MD
  Peer
- Erica L. Mayer, MD, MPH
  Peer
- Peter Schmid, FRCP, MD, PhD
  Peer
1.50 program credits
Management of HR+, HER2- High-Risk EBC
MinuteCE®
Management of HR+, HER2- High-Risk EBC
- Erica L. Mayer, MD, MPH
  Peer
1.50 program credits
Management of HER2-Low MBC Following First-Line Disease Progression
MinuteCE®
Management of HER2-Low MBC Following First-Line Disease Progression
- Peter Schmid, FRCP, MD, PhD
  Peer
1.50 program credits

Program Chapters

Segment Chapters

Playlist:

Recommended